Video Experimental Relacionado
Updated: Aug 15, 2026
09:39
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
Published on: January 27, 2014
Escintigrafía de talio de estrés farmacológico con 2-ciclohexilmetilidenhidrazinoadenosina (WRC-0470). Un nuevo
1Department of Medicine, University of Virginia Health Sciences Center, Charlottesville 22908, USA. dkg2w@virginia.edu
Circulation
|October 1, 1996
Resumen
Un nuevo agonista selectivo del receptor de adenosina A2A, WRC-0470, dilata efectivamente las arterias coronarias para la imagen del estrés sin causar efectos secundarios. Esto ofrece una alternativa más segura para los pacientes sometidos a pruebas de estrés farmacológicas.
Área de la Ciencia:
- Cardiología Cardiología.
- Farmacología Farmacología.
- Imágenes médicas de imágenes médicas.
Sus antecedentes:
- Los agentes farmacológicos de imágenes de estrés como la adenosina pueden causar efectos secundarios significativos debido a la estimulación no selectiva del receptor de adenosina.
- Estos efectos secundarios incluyen hipotensión, dolor en el pecho y broncospasmo, lo que limita su uso en ciertos pacientes.
Objetivo del estudio:
- Evaluar un nuevo agonista selectivo del receptor de adenosina A2A (WRC-0470) como un agente potencial para las imágenes de perfusión por estrés farmacológico.
- Para determinar si WRC-0470 puede inducir la vasodilatación coronaria sin los efectos adversos asociados con los agonistas no selectivos de los receptores de adenosina.
Principales métodos:
- Se administró WRC-0470 a perros de pecho abierto, evaluando la vasodilatación de la arteria coronaria relacionada con la dosis y la estabilidad hemodinámica.
- Respuestas hemodinámicas comparadas y vasodilatación coronaria de WRC-0470 versus adenosina en perros con estenosis coronaria inducida.
- Utilizó la inyección 201T1 en la tensión máxima para la imagen de perfusión para evaluar los defectos del miocardio.
Principales resultados:
- WRC-0470 produjo una vasodilatación dependiente de la dosis en las arterias coronarias descendente anterior izquierda (LAD) y circunflejo izquierdo (LCx) sin afectar la frecuencia cardíaca o la presión arterial.
- La administración de adenosina dio lugar a una hipotensión significativa, lo que limitó su uso.
- WRC-0470 aumentó el flujo sanguíneo LCx significativamente sin hipotensión, y las imágenes de perfusión revelaron defectos anterosépticos en perros con estenosis LAD.
Conclusiones:
- El agonista selectivo de la adenosina A2A WRC-0470 es un vasodilatador coronario de acción corta y potente.
- WRC-0470 demuestra el potencial como un agente seguro y eficaz para las imágenes de perfusión por estrés farmacológico.
Videos de Conceptos Relacionados
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
01:30Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...